<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03916757</url>
  </required_header>
  <id_info>
    <org_study_id>Imm008</org_study_id>
    <nct_id>NCT03916757</nct_id>
  </id_info>
  <brief_title>V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer</brief_title>
  <acronym>GBM</acronym>
  <official_title>Open-label Phase II Trial of the Safety and Efficacy of V-Boost in Patients With Refractory Glioblastoma Multiforme (GBM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunitor LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunitor LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Phase II study to determine the safety and efficacy of V-Boost in treating a type of&#xD;
      brain cancer called Glioblastoma Multiforme (GBM). V-Boost is an immunotherapy in which the&#xD;
      patient's immune system will be modulated to eliminate tumor cells. V-Boost is made as an&#xD;
      oral tablet which contains specially formulated hydrolyzed GBM antigens along with&#xD;
      alloantigens. Patients are either newly diagnosed or with recurrent form of GBM who may have&#xD;
      been subjected to surgery and/or chemo- or radiation therapy that ended up unsuccessful. The&#xD;
      goal is to eradicate GBM tumor cells through daily oral administration of one pill of V-Boost&#xD;
      immunotherapeutic vaccine, which so far has not shown any adverse reaction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed Phase II trial is an-open label study of the safety and efficacy of V-Boost in&#xD;
      newly diagnosed or treatment-refractory patients with glioblastoma multiforme (GBM) following&#xD;
      unsuccesfull resection and/or chemoradiation. The Phase I clinical tria,l carried out in a&#xD;
      small, open-label study, demonstrated safety and promising efficacy. The purpose of this&#xD;
      study is to gain additional information from a larger clinical trial aimed to recruit at&#xD;
      least 20 patients with GBM. Patients may be newly diagnosed with GBM or are those who have&#xD;
      been subjected to resection and/or chemotherapy or radiation, but without success. Patients&#xD;
      need to have imaging records and health assessment prior to study enrollment. Those on&#xD;
      chemotherapy or radiation can be in washout period or may receive immunotherapy concurrently.&#xD;
      Patients will be administered daily dose of V-Boost oral tablet for at least one month and&#xD;
      additional dosing can be envisaged depending on outcome of first month. The primary objective&#xD;
      is to evaluate the effect on tumor size and progression free survival (PFS) in comparison to&#xD;
      patients on standard of care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 16, 2019</start_date>
  <completion_date type="Anticipated">June 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All patients who passed eligibility requirement will receive daily dose of V-Boost</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is open label study, no masking is required</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on tumor size</measure>
    <time_frame>3 months</time_frame>
    <description>Imaging of brain at 3-month time post-therapy and comparison to baseline records</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on progression-free survival</measure>
    <time_frame>3 months</time_frame>
    <description>Evaluation of patients status on progression free survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Glioma of Brain</condition>
  <arm_group>
    <arm_group_label>V-Boost recipients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this open label study all eligible participants will receive daily tablet of V-Boost</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V-Boost</intervention_name>
    <description>Open label setting</description>
    <arm_group_label>V-Boost recipients</arm_group_label>
    <other_name>V-Boost Immunitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of GBM&#xD;
&#xD;
          -  â‰¥ 5 years of age&#xD;
&#xD;
          -  Consent from parents or legal guardian if under-aged&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe pulmonary, cardiac or other systemic disease&#xD;
&#xD;
          -  Presence of an acute infection requiring active treatment with antibiotics/antivirals&#xD;
&#xD;
          -  Receiving corticosteroids (e.g., dexamethasone) during study duration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aldar Bourinbayar, MD/PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Immunitor LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aldar Bourinbaiar, MD/PhD</last_name>
    <phone>+97695130306</phone>
    <email>immunitor@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Galyna Kutsyna, MD</last_name>
    <phone>+97695130306</phone>
    <email>kutsynagalyna@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Immunitor LLC</name>
      <address>
        <city>Ulaanbaatar</city>
        <country>Mongolia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aldar Bourinbaiar, MD</last_name>
      <phone>97695130306</phone>
      <email>aldar@immunitor.com</email>
    </contact>
    <contact_backup>
      <last_name>Aldar Bourinbayar, MD</last_name>
      <phone>+97695130306</phone>
      <phone_ext>Bourinbayar</phone_ext>
      <email>immunitor@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Aldar Bourinbaiar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mongolia</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/28443252</url>
    <description>link to similar study</description>
  </link>
  <reference>
    <citation>Tarakanovskaya MG, Chinburen J, Batchuluun P, Munkhzaya C, Purevsuren G, Dandii D, Hulan T, Oyungerel D, Kutsyna GA, Reid AA, Borisova V, Bain AI, Jirathitikal V, Bourinbaiar AS. Open-label Phase II clinical trial in 75 patients with advanced hepatocellular carcinoma receiving daily dose of tableted liver cancer vaccine, hepcortespenlisimut-L. J Hepatocell Carcinoma. 2017 Apr 12;4:59-69. doi: 10.2147/JHC.S122507. eCollection 2017.</citation>
    <PMID>28443252</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 10, 2019</study_first_submitted>
  <study_first_submitted_qc>April 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

